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Mammalian DNA is methylated at many CpG dinucleotides. The
biological consequences of methylation are mediated by a family
of methyl-CpG binding proteins1–4. The best characterized family
member is MeCP2, a transcriptional repressor that recruits his-
tone deacetylases5–7. Our report concerns MBD2, which can bind
methylated DNA in vivo and in vitro4 and has been reported to
actively demethylate DNA (ref. 8). As DNA methylation causes
gene silencing, the MBD2 demethylase is a candidate transcrip-
tional activator. Using specific antibodies, however, we find here
that MBD2 in HeLa cells is associated with histone deacetylase
(HDAC) in the MeCP1 repressor complex1,9. An affinity-purified
HDAC1 corepressor complex10,11 also contains MBD2, suggesting
that MeCP1 corresponds to a fraction of this complex. Exogenous
MBD2 represses transcription in a transient assay, and repression
can be relieved by the deacetylase inhibitor trichostatin A (TSA;
ref. 12). In our hands, MBD2 does not demethylate DNA. Our
data suggest that HeLa cells, which lack the known methylation-
dependent repressor MeCP2, use an alternative pathway invol-
ving MBD2 to silence methylated genes.
Previous work showed that Mbd2b, a truncated form of mouse
Mbd2 (Fig. 1a), binds DNA in vitro in a methylation-dependent
manner4. Full-length recombinant mouse MBD2a (Fig. 1a) also
formed a complex with a densely methylated probe in a bandshift
assay, but did not bind to non-methylated counterpart (Fig. 1b). To
search for MBD2-associated proteins, we first raised polyclonal
antisera against recombinant MBD2. Antibodies were tested on
western blots of HeLa nuclear extract and assessed for their ability
to discriminate between MBD2 (in particular the MBD3-like
MBD2b form) and its relative, MBD3 (ref. 4). Antiserum S923
bound to recombinant MBD2b, but not to MBD3 (Fig. 1c). Anti-
serum R593 recognized MBD2b and cross-reacted with MBD3
(Fig. 1c). In HeLa extract, S923 antibodies detected an approxi-
Fig. 1 MBD2a binds methylated DNA specifically and is part of the methyl-CpG binding complex, MeCP1. a, Maps of full-length MBD2a and a hypothetical trun-
cated form, MBD2b, that initiates at a downstream methionine4. b, Recombinant MBD2a forms a complex with probe MeCG11 (26 methyl-CpGs), but not with
the non-methylated form CG11. c, Anti-MBD2 antisera S923 and R593 probed against western blots of HeLa nuclear extract (26 µg protein; HeLa NE), recombi-
nant MBD2b (30 ng; ref. 4) and recombinant MBD3 (30 ng; ref. 4). d, Immunoprecipitates with anti-MBD2 antiserum S923 (αMBD2) contained only the 48-kD
MBD2a protein. MBD2a always resolves as a doublet band for unknown reasons; the doublet resolves less well at higher concentrations of antibody due to the
increased presence of closely migrating IgG. The control was pre-immune serum (PI). e, S923 anti-MBD2 antibodies supershift the bandshift complex between
MeCP1 and the methylated DNA probe MeCG11. No supershift was seen with pre-immune serum or of the non-specific CG11 complex (PI). f, Depletion of MBD2
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mately 49-kD band corresponding to full-length
MBD2a (in vitro-translated MBD2a has an identical
mobility; data not shown), plus an approximately 30-kD
band that may be MBD2b or a degradation product.
S923 does not cross-react with MeCP2, MBD1 or MBD4
(data not shown). We further tested the specificity of the
S923 antiserum against soluble nuclear proteins by
probing western blots of S923 immunoprecipitates with
the less-specific R593 antiserum. R593 recognizes
MBD3 (Fig. 1c), but only MBD2a was detected in the
precipitated material (Fig. 1d).
We used the highly specific S923 antiserum to deter-
mine whether MBD2 is a component of the methyl-
CpG binding activity (MeCP1; ref. 1) previously
implicated as a transcriptional repressor9,13. S923 anti-
bodies were able to quantitatively supershift the
MeCP1 complex with a probe methylated at multiple
sites, whereas pre-immune serum was inert (Fig. 1e, MeCG11
lanes). A non-specific complex with the non-methylated probe9
was unaffected by either immune or pre-immune sera (Fig. 1e,
CG11 lanes). When we used anti-MBD2 antibodies to deplete
MBD2 from the HeLa extract, the MeCP1 complex was corre-
spondingly depleted (Fig. 1f). Pre-immune serum did not deplete
the MeCP1 complex, and neither antiserum affected the non-
specific complex with non-methylated DNA. We conclude that
MBD2 is a component of the MeCP1 complex.
Several studies have indicated that methylation-dependent
transcriptional repression involves deacetylation6,7,14–17. As
MeCP1 is a likely repressor of methylated genes9, we asked
whether its constituent MBD2 is associated with deacetylases. We
found that S923 immunoprecipitates contained up to 27% of the
total histone deacetylase activity of HeLa extracts (Fig. 2a).
Moreover, anti-HDAC1 antibodies efficiently immunodepleted
both MeCP1 (Fig. 2b) and MBD2 (Fig. 2c) from the extract,
whereas control non-immune serum had no effect. In addition,
several known protein components of corepressor complexes
were co-immunoprecipitated by MBD2 antibodies from a HeLa
extract (Fig. 2d), indicating that MeCP1 activity is due to a com-
plex between MBD2, deacetylases HDAC1 and HDAC2, and
RbAp48. As a negative control, we found that retinoblastoma
protein, which associates with HDACs (refs 18–20), was not
immunoprecipitated by anti-MBD2 (data not shown). Mass fin-
gerprinting analysis of proteins affinity-purified using an anti-
HDAC1 antibody11 (Fig. 2e) indicated that MBD2 is a compo-
nent of a corepressor complex. Western-blot analysis confirmed
that MBD2 is present in complexes affinity purified with HDAC1
antibodies, together with HDAC1/2-associated proteins RbAp46
and RbAp48 (Fig. 2f).
A previous report claimed that a related methyl-CpG binding
protein, MBD1, is a component of MeCP1 (ref. 3). Subsequent
experiments with antibodies highly specific for MBD1 failed to
supershift or immunodeplete MeCP1 (H.-H.N. and A.B., unpub-
lished data) or to immunoprecipitate deacetylase activity (Fig. 2a).
These and other results lead us to suspect that the anti-MBD1 anti-
body used in the previous study may have cross-reacted with MBD
proteins that were unknown at the time. Recent work confirms the
proposal3 that MBD1 is a methylation-dependent transcriptional
repressor, but argues against its involvement in MeCP1 of HeLa
cells (H.-H.N. and A.B., unpublished data).
HeLa cells lack detectable amounts of the known methylation-
dependent repressor MeCP2 (Fig. 3a), but are nevertheless able to
repress transfected methylated genes9. We initially determined
whether repression in the effective absence of MeCP2 was HDAC
dependent by transiently transfecting a luciferase reporter gene
that contained a cluster of 20 methylatable HhaI sites (CG11)
immediately upstream of the SV40 promoter (Fig. 3b,c). The
M.HhaI-methylated reporter construct was transcribed at approx-
imately 30% of the level seen in non-methylated controls (Fig. 3b).
The same construct lacking the CG11 cluster (originally used to
Fig. 2 MBD2 is associated with histone deacetylases in the MeCP1
complex. a, Anti-MBD2 antibodies co-immunoprecipitate HDAC
activity from HeLa cell extracts, but pre-immune serum (PI) and
control antibodies against MBD1 and CDK7 do not. b,c, Anti-
HDAC1 antibodies (10, 20 and 30 µl) deplete MeCP1 bandshift
activity (b) and MBD2 (c) from a HeLa nuclear extract. Control non-
immune serum does not deplete MeCP1 or MBD2. MBD2 was
detected by western blot using S923 antiserum. d, Anti-MBD2 anti-
bodies co-immunoprecipitate HDAC1, HDAC2 and RbAp48 from
HeLa nuclear extracts. Co-migration with immunoglobulin heavy
chain leads to aberrant migration of RbAp48 in the immunopre-
cipitated lane. e, Polypeptides retained on HDAC1 (αHDAC1) and
GST (αGST) antibody columns after separation by SDS–PAGE fol-
lowed by silver staining. Known components of the complex11 are
labelled (right). Mass spectrometric and sequence analysis of the
43-kD band from the fraction isolated using anti-HDAC1 antibod-
ies identified a peptide (VLYIDIDIHHGDGVEEAFYTTDR) contained
in HDAC1, as well as a peptide (GLQGVGPGSNDETLLSAVASALHTSS-
APITGQVSAAVEK) that matches the MBD2 sequence. It is not
known whether HDAC1* represents an alternative form or degra-
dation product of HDAC1. The data suggest roughly equimolar
amounts of HDAC1* and MBD2 in this band (data not shown). f,
MBD2a, RbAp46, RbAp48 and HDAC1 were detected by western
blot in nuclear extract (input) and in complexes that were affinity
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identify MeCP1 activity1) was minimally repressed
by HhaI site methylation (X. Nan and A.B., unpub-
lished data). TSA treatment reduced methylation-
dependent repression (Fig. 3b), indicating that
deacetylation is involved. We next asked whether
MBD2 was itself a repressor by transiently express-
ing MBD2a fused to the Gal4 DNA-binding
domain. Transcription of a co-transfected reporter
gene encoding the human DNA polymerase-β pro-
moter (plus Gal4 DNA-binding sites) was inhibited
by Gal4-MBD2a, but repression was abolished by
TSA (Fig. 3d). A reporter under control of the
human ACTB (encoding β-actin) promoter was
also repressed by the fusion protein, but repression
was weakly reduced by TSA (Fig. 3e). Promoter-
specific responses to derepression by TSA have been
observed20 previously. Repression of both promot-
ers depended on the presence of Gal4-binding sites
in the reporter construct (data not shown). The
results indicate that repression of at least some pro-
moters by MBD2 depends on deacetylation.
Given the unexpected association of a putative demethylase with
transcriptional repression complexes, we tested the demethylation
activity of in vitro-translated mouse4 or human8 MBD2b expres-
sion constructs. Translation products complexed with methylated
DNA (Fig. 4a), indicating correct protein folding, but methylated
CCGG and GCGC sites in the same probe (Fig. 4c) were not sus-
ceptible to HpaII or HhaI after prolonged incubation under pub-
lished conditions8 (Fig. 4b). Moreover, we did not observe
dissociation of the MBD2 bandshift complexes due to demethyla-
Fig. 3 MBD2 can account for deacetylase-dependent repres-
sion of methylated genes in HeLa cells. a, Western blots show
that MeCP2 is not detectable in HeLa extracts (26 µg), but is
abundant in rat brain extracts (20 µg). Controls show that
mSin3A is present in both extracts. b, Transcription of the
transiently transfected CG11-pGL2 construct (c) is repressed by
methylation of HhaI sites (HhaI M+), but not by mock methy-
lation (mock M–). Repression is relieved by 100 ng/ml TSA. Per
cent relative activity of the promoters is expressed as the ratio
of luciferase to β-galactosidase activities. c, Map of reporter
gene constructs. CG11-pGL2 contains 45 methylatable HhaI
sites, including the promoter-proximal CG11 cluster. Compari-
son of DNA polymerase-β and β-actin promoter constructs,
each with five Gal4 binding sites. The SV40 enhancer is
marked (Enh). d,e, Co-transfection of a construct encoding
MBD2a fused to the Gal4 DNA-binding domain together with
the DNA pol β (d) or β-actin (e) reporters into mouse L cells
causes transcriptional repression. Relative activities are the
ratios of luciferase to β-galactosidase (d) or β-galactosidase to
luciferase (e) activities. TSA (100 ng/ml) relieves repression of
the DNA pol β reporter.
Fig. 4 Absence of demethylation by in vitro-trans-
lated MBD2b. a, DNA probe MeCG11 was 32P end
labelled and incubated with no protein (lane 1),
in vitro translation products of MBD2b expression
constructs pETMbd2b (lane 2; ref. 4) or pHis-
dMTase8 (lane 3), or with a mock in vitro-transla-
tion reaction (lane 4). Differing mobilities of
complexes on 8% polyacrylamide gels (compare
lanes 2,3) is probably due to the greater size of
the pHis-dMTase protein (37 kD) compared with
pETMbd2b protein (30 kD). b, MeCG11 is suscepti-
ble to MspI (M), but remains resistant to HpaII (H)
and HhaI (Hh) after a 3-h incubation with either
human (ms) or mouse (bh) MBD2b. The asterisked
band is a probe contaminant. c, The 160-bp
duplex probe MeCG11 contains 19 HhaI sites
(short barbed arrows) and 7 HpaII sites (long
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tion of binding sites during the prolonged assay (Figs 1b and 4a).
Attempts to demethylate other oligonucleotide and plasmid sub-
strates with bacterially expressed MBD2, in vitro-translated
MBD2b or anti-MBD2 immunoprecipitates from HeLa extracts
were similarly unsuccessful (data not shown). It may be that
MBD2 has a dual role as both a DNA methylation-dependent
repressor and an activator of genes that are silenced by methyla-
tion. Diametrically opposed activities might theoretically be com-
bined in a protein that serves as a switch between active and
inactive chromatin states. This speculative hypothesis depends,
however, on verification of the demethylase activity of MBD2.
Our data uncover a novel mediator of methylated gene silencing.
Although MeCP2 and MBD2 both repress transcription of methy-
lated DNA via a deacetylase-containing corepressor complex, there
are differences between them. Tightly bound MeCP2 (refs 2,21)
has the character of a structural component of the chromosome
that ensures long-term silencing of methylated sequences.
MBD2/MeCP1, on the other hand, is released from nuclei by low
salt1, suggesting that it is not stably complexed with DNA. The
MeCP1 subset of the HDAC corepressor complex may be a cat-
alytic complex that alters methylated DNA-containing chromatin
during a transient visit. There is also a difference in binding speci-
ficity between MeCP1 and MeCP2. MeCP2 binds to single methy-
lated sites22, whereas MeCP1 requires regions of dense CpG
methylation1. Conceivably, each MeCP1 complex contains multi-
ple molecules of MBD2, thereby enhancing binding to local clus-
ters of methyl-CpG. Assessment of this possibility awaits future
purification and compositional analysis of MeCP1. Already, the
differences between MBD2 and MeCP2 suggest that they may have
somewhat different roles in transcriptional silencing.
Methods
Plasmids. We constructed plasmid pCMV-Gal4-MBD2a by inserting a
NaeI/SspI fragment of MBD2a cDNA (ref. 4) into BamHI-blunted pCMV-
Gal4 vector5 and pGEX5-MBD2a by inserting the same NaeI/SspI fragment
of MBD2a cDNA into BamHI-blunted pGEX5x1 vector (gift from S. Mac-
Neill). We sequenced all constructs to confirm identity. CG11-pGL2
luciferase reporter was a gift from X. Nan (unpublished data). Plasmid
pHis-dMTase was a gift from M. Szyf8. The Gal4-DNA polymerase-β
luciferase reporter23 was a gift from J. Millbrandt.
Transfection and reporter assays. We transfected mouse fibroblast L cells
and β-galactosidase assays essentially as described5,6 and detected
luciferase activity using a luciferase assay kit (Promega). Transfection mix-
es included reporter (2 µg; with Gal4-binding sites), effector (2 µg; Gal4-
MBD2a) and internal control reporter (2 µg; either human ACTB promot-
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er driving β-galactosidase or pGL2 SV40 promoter/enhancer driving
luciferase). We transfected HeLa cells with CG11-pGL2 luciferase reporter
(1 µg; either mock methylated or methylated with HhaI methyltransferase)
and human β-actin/β-galactosidase reporter (1 µg) using Lipofectamine
(Gibco BRL) according to the manufacturer’s instructions. We treated cells
with TSA (100 ng/ml) for 24 h before collection.
Bandshifts, immunodepletion and immunoprecipitation assays. We per-
formed bandshift assays as described3. For immunodepletion of MBD2 or
MeCP1 activity, we immobilized the antibodies (5–30 µl serum) on pro-
tein-G sepharose (Pharmacia). After washing the beads with PBS (plus 1 M
NaCl and 0.1% Triton X-100) and binding buffer (50 mM Hepes, pH 7.9,
150 mM NaCl, 0.5 mM EDTA, 10% glycerol, 0.1% Triton X-100), we incu-
bated the beads with HeLa nuclear extract (40 µg) in binding buffer for 2 h
at 4 °C. Aliquots of the supernatant were then used for bandshift and west-
ern-blot analysis. We performed immunoprecipitations as described6. For
immunoprecipitation of histone deacetylase activity6, we used HeLa whole
cell extract, lysed in Tris (50 mM, pH 8.0), NaCl (150 mM), EDTA (0.5
mM), EGTA (0.5 mM), 1% NP40, β-mercaptoethanol (5 mM) and pro-
tease inhibitors, as input.
Antibodies, western blots and affinity purification. Antibody S923 was
raised in sheep against GST-MBD2a fusion protein. In this preparation of
affinity-purified recombinant protein, only 20% was full length, so the
sample was biased toward the tagged amino-terminal portion of MBD2a.
Antibody R593 was raised in rabbit against GST-MBD2b fusion protein.
Anti-mSin3A (AK11), anti-HDAC2 (H-52) and anti-Rb (C-15) were pur-
chased (Santa Cruz). Anti-RbAp48 was raised against the synthetic peptide
CENIYNDEDPEGSVDPEGQGS as described24. Antibodies against
MeCP2 (ref. 5) have been described. We performed western blots as
described3, except the buffer used was Tris HCl (50 mM, pH 8.0), NaCl
(150 mM), 0.05% Tween-20 and 1% dried milk powder. Complexes were
affinity purified using anti-HDAC1 antibodies as described11.
Demethylase assays. We carried out in vitro transcription/translation of
MBD2 expression plasmids and demethylase assays as described8. We
analysed restriction digests of MeCG11 probe by electrophoresis on 8%
polyacrylamide gels.
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